SCHAUMBURG, Ill., Feb. 9 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched Cefazolin for injection, USP, an essential antibiotic used to treat serious infections, in a 500mg single-dose vial.
The 500mg single-dose vial expands Sagent's existing line of Cefazolin products beyond the 1g single-dose vials and 10g pharmacy bulk package vials launched in March 2008. All doses are completely latex-free and include enhanced packaging features such as bar-coding and labeling designed to reduce confusion among doses.
"The innovative labeling we brought to our other Cefazolin products is now available on a 500 mg single-use vial, allowing clinicians access to an extended line of Cefazolin for injection designed with medication safety in mind," said Lorin Drake vice president of sales and marketing at Sagent Pharmaceuticals. "Our enhanced Cefazolin packaging designs incorporate specific features in response to needs expressed by our customers. We are proud to provide practical solutions designed to improve the safety and care of patients in the dose sizes most needed."
Sagent will begin marketing and shipping Cefazolin in the 500mg single-dose vials immediately.
Cefazolin for injection, USP, is the generic equivalent of KEFZOL(R), an
antibiotic used to treat bacterial infections. Cefazolin for injection, USP,
is indicated for serious infections such as those of the respiratory, biliary
and urinary tracts, skin and skin structure infections, bone and joint
infections, and other infections caused by E. coli, S. pneumoniae, S. aureus,
and various strains of streptococci. Prophylactic Cefazolin for injection,
USP, preoperative, intraopertative and postoperative administration can be
effective in reducing the incidence of certain surgical infections. The most
common adverse e
|SOURCE Sagent Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved